SeaStar Medical Holding Corporation (ICU) Stock Analysis
SeaStar Medical is a highly speculative, binary micro-cap where pediatric QUELIMMUNE validates a novel immunomodulation platform, but the investment outcome hinges on adult AKI trial success, FDA approval, dilution control, and access to a multibillion-dollar critical-care market.
Overview
SeaStar Medical is a commercial-stage micro-cap medical device company developing extracorporeal immunomodulation therapies for hyperinflammation and organ failure. Its approved pediatric product, QUELIMMUNE, uses the patented Selective Cytopheretic Device to deactivate inflammatory immune cells in critically ill children with AKI from sepsis requiring CRRT. Clinical data show 77% Day-60 survival and complete renal recovery among survivors, while economic studies suggest meaningful hospital cost savings. Current revenue is tiny and U.S.-only, but the platform’s adult AKI opportunity could be transformative if pivotal trial results support FDA approval.